The COVID-19 Pandemic – Webinars and Online Events

In this webinar, our expert speaker Dr. Ceri Fielding, from the division of infection and immunity at Cardiff University, will discuss the need to understand how viruses interact with NK cells during the development of novel antiviral therapies.

Speaking at the Vaccine Research & Development 2022, Kyle Luttgeharm, PhD, Product Manager from Agilent presented their talk on IVT RNA production and
accurate and precise mRNA analysis.

In this webinar, Dr. Catherine Houlihan, will describe an unrecognized case of viral hemorrhagic fever imported into the UK and the important lessons learned for the emergency clinicians, GPs, virologists, infection specialists and public health doctors.

Over recent years, genomic sequencing of pathogens has emerged as a powerful tool to guide public health action by providing a deeper understanding of pathogen evolution, emerging variants and transmission dynamics. Oxford Nanopore Technologies offers an accessible, all-in-one sequencing platform that enables rapid, distributed and scalable genomic pathogen surveillance.

In this webinar, you will hear from leaders in the field of microbiology and infectious disease research, who will share their experiences in developing and implementing fast and accessible pathogen surveillance protocols with nanopore sequencing. The protocols presented in this webinar can be leveraged for targeted whole genome sequencing of different viral pathogens such as SARS-CoV-2 and monkeypox virus, as well as more broadly for the genomic characterization of known and novel viruses in an untargeted manner.

Speaking at The Landscape of Cancer Research 2022, Nicholas Abuid, PhD from ACROBiosystems, presented his talk on providing high purity, customizable, and bioactive reagents to support research and translation in cancer immune therapy. Their catalogue ranges in targets for various diseases.

In this webinar, we will explore the common challenges encountered by developers and manufacturers when developing PCR tests, and how these challenges can be overcome with the right technologies.

To combat the COVID-19 pandemic, comprehensive characterization of humoral and cellular immune responses to SARS-CoV-2 is essential.

Antiviral drugs that slow SARS-CoV-2 replication in patient cells are critical for curbing the pandemic. For RNA viruses such as SARS-CoV-2, genome duplication hinges on RNA polymerase, making the enzyme an ideal therapeutic target for drug development.

Analysis of SARS-CoV-2-specific T cells is important in understanding their role during acute disease and in long-term protection. Find out about some of the tools used in T-cell research and the promise they show as a cell therapy for COVID-19.

These technologies can help identify new strategies to enhance myocardial repair and regeneration through target validation and manipulation.